Abstracts

Search by keyword or author name.

Showing 734 abstracts.

IMPAACT P1066: raltegravir (RAL) safety and efficacy in HIV infected (+) youth two to 18 years of age through week 48

Conference

XIX International AIDS Conference

Study

P1066 (Y)

Size and Decay of the Resting CD4+ T Cell Latent HIV Reservoir in Early-Treated Infants.

Conference

XIX International AIDS Conference

Study

P1030 (Y)

Pharmacokinetics, Safety, and Efficacy of Dolutegravir (DTG; S/GSK1349572) in HIV-1 Infected Adolescents: Preliminary analysis from IMPAACT 1093

Conference

XIX International AIDS Conference

Study

P1093 (Y)

Predictors of Tuberculosis Disease in HIV-infected and HIV-exposed uninfected children from Southern Africa: IMPAACT P 1041 study

Conference

XIX International AIDS Conference

Study

DACS 646 (Y), P1041 (Y)

Association between nevirapine-resistant HIV-variants and antiretroviral treatment outcomes in single-dose nevirapine exposed infants.

Conference

XIX International AIDS Conference

Study

P1060 (Y)

HIV-1 viral kinetics among in utero and intrapartum infected infants in NICHD HPTN 040/ PACTG 1043.

Conference

XIX International AIDS Conference

Study

P1043/HPTN 040 (Y)

Impact of body weight on the risk of low lopinavir/r concentrations during the third trimester of pregnancy in HIV-infected Thai and US Women

Conference

13th International Workshop on Clinical Pharmacology of HIV Therapy

Study

DACS 652 (Y)

Raltegravir (RAL Pharmacokinetics (PK) and Safety in Neonates (IMPAACT P1097)

Conference

13th International Workshop on Clinical Pharmacology of HIV Therapy

Study

P1097 (Y)

Effect of Pregnancy on Pharmacokinetics of Boosted Indinavir

Conference

13th International Workshop on Clinical Pharmacology of HIV Therapy

Study

P1026S (Y)

Interim Results from IMPAACT P1066: Raltegravir Oral Granules Formulation in Children 6 months to <2 Years of Age

Conference

19th Conference on Retroviruses and Opportunistic Infections

Study

P1066 (Y)